Skip to main content
OpenTrials

Clinical trial condition

Fabry Disease

Explore clinical trials studying Fabry Disease. Study availability and eligibility vary by location and protocol.

158 public trials 34 recruiting studies
Refine in advanced search Browse all conditions

Fabry Disease trial results

Completed

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

NCT03500094

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • Clinical Study Site Tampa, Florida, United States
  • Clinical Study Site Atlanta, Georgia, United States
  • Clinical Study Site Minneapolis, Minnesota, United States
  • Clinical Study Site Columbia, Missouri, United States
View Trial Details
Completed

Replagal Enzyme Replacement Therapy for Children With Fabry Disease

NCT00084084

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +20 more
Locations
  • Tucson Access Center of Arizona Kidney Disease Hypertension Center Tucson, Arizona, United States
  • University of Arizona Health Sciences Center Tucson, Arizona, United States
  • Children's Physician Group Palm Beach Gardens, Florida, United States
  • Christus St. Patrick Hospital Lake Charles, Louisiana, United States
View all 14 locations
View Trial Details
Completed

This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.

NCT01304277

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • University of Alberta Hospital Edmonton, Alberta, Canada
  • Queen Elizabeth II Health Sciences Centre Halifax, Nova Scotia, Canada
  • The Hospital for Sick Children Toronto, Ontario, Canada
  • INC Research Toronto, Ontario, Canada
View Trial Details
Completed

Safety Study of Replagal® Therapy in Children With Fabry Disease

NCT01363492

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • Emory Division of Medical Genetics Decatur, Georgia, United States
  • Duke University Medical Center Durham, North Carolina, United States
  • Baylor University Medical Center Dallas, Texas, United States
  • University of Utah Hospital Salt Lake City, Utah, United States
View Trial Details
Completed

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

NCT00864851

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • AKDHC Tucson Access Center Tucson, Arizona, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • New York Unversity School of Medicine New York, United States
  • O & O Alpan, LLC Springfield, Virginia, United States
View Trial Details
Completed

Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease

NCT01124643

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • O&O Alpan LLC Fairfax, Virginia, United States
  • The Royal Melbourne Hospital Parkville, Australia
  • 1st School of Medicine Charles University Prague, Czechia
View Trial Details
Completed

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

NCT01298141

Conditions
Brain Diseases, Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, +19 more
Locations
  • Alberta Children's Hospital Calgary, Alberta, Canada
  • University of Alberta Hospital Edmonton, Alberta, Canada
  • Vancouver General Hospital Vancouver, British Columbia, Canada
  • University of Manitoba Winnipeg, Manitoba, Canada
View Trial Details

Related conditions